MedPath

Serum activin, gene expression, muscle mass and function in people with critical illness (SAGE-MUSCLE): an observational cohort study

Not Applicable
Completed
Conditions
Intensive Care Unit Aquired Weakness
Physical Medicine / Rehabilitation - Physiotherapy
Registration Number
ACTRN12615000047594
Lead Sponsor
Footscray Hospital Western Health
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
36
Inclusion Criteria

Have invasive mechanical ventilation for at least 48 hours and;
Are expected to be in ICU for at least 120 hours

Exclusion Criteria

Aged < 18;
They have a proven or suspected acute primary neurological process likely to result in global impairment of conscious level/cognition or prolonged weakness or;
Death is deemed imminent or inevitable.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum activin level[Daily until discharge from ICU];Needle muscle biopsy of the quadriceps with ultrasound guidance will be required to allow extraction of RNA. Target genes will be analysed by reverse transcription polymerase chain reaction (RT-PCR).[120 hours after admission to ICU];Six-Minute Walk test[On acute hospital discharge]
Secondary Outcome Measures
NameTimeMethod
Grip Strength measured with a hand held dynamometer.[On awakening; first standing occasion; discharge to ward and discharge from acute hospital.];Knee extension strength knee measured using Medical Research Council Scale for manual muscle testing.[On awakening; first standing occasion; discharge to ward and discharge from acute hospital.];Timed Up and Go Test.[On acute hospital discharge.];Physical Function in ICU test (PFIT)[On first standing occasion and on discharge to ward];Discharge destination[On discharge from acute hospital];ICU length of stay[On discharge from ICU];Hospital length of stay[On discharge from acute hospital]
© Copyright 2025. All Rights Reserved by MedPath